可互换生物类似药市场（2026—2031）
可互换生物类似药市场规模预计由2026年的36.2亿美元增至2031年的49.6亿美元，预测期复合年增长率为6.50%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
可互换生物类似药市场规模预计由2026年的36.2亿美元增至2031年的49.6亿美元，预测期复合年增长率为6.50%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 6.5% | 机构预测 |
| 市场规模 | 2026 | USD 3.62 billion | 机构预测 |
| 市场规模 | 2031 | USD 4.96 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| distribution_channel | specialty pharmacies | 2025 | 45.880% |
| end_user | hospitals and clinics | 2025 | 54.660% |
| geography | North America | 2025 | 40.350% |
| therapeutic_area | autoimmune and inflammatory diseases | 2025 | 39.760% |
关键结论
- distribution_channel 维度中，specialty pharmacies 在 2025 年的公开份额为 45.88%。
- end_user 维度中，hospitals and clinics 在 2025 年的公开份额为 54.66%。
- geography 维度中，North America 在 2025 年的公开份额为 40.35%。
- therapeutic_area 维度中，autoimmune and inflammatory diseases 在 2025 年的公开份额为 39.76%。
主要参与者
- Amgen Inc.
- Celltrion, Inc.
- Pfizer Inc.
- Biocon Biologics Limited
- Sandoz Group AG
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High-value biologic patent expiries | +1.800% | Global, with concentrated gains in North America and Europe | Medium term (2-4 years) |
| Pharmacy-level substitution potential | +1.300% | North America primary, Europe member-state dependent | Short term (≤ 2 years) |
| Payer pressure to reduce biologic treatment costs | +1.100% | North America and EU | Short term (≤ 2 years) |
| Expansion of interchangeable designations across major molecules | +0.900% | North America, with spillover to APAC regulatory convergence | Medium term (2-4 years) |
| Formulary automation and specialty pharmacy dispensing data | +0.500% | North America core, with emerging EU centralized procurement interest | Short term (≤ 2 years) |
| Demand capture in underserved treatment channels | +0.400% | Asia-Pacific, Middle East and Africa, and South America | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Variation in automatic substitution laws | -0.500% | United States, with state differences in notification, recordkeeping, and cost-equivalence requirements | Short term (≤ 2 years) |
| Reimbursement and channel-contracting complexity | -0.400% | North America and the EU | Medium term (2-4 years) |
| Interchangeability confusion among prescribers and patients | -0.300% | Global | Short term (≤ 2 years) |
| Limited manufacturing flexibility for complex cold-chain and device operations | -0.200% | Global, with an acute impact in the Middle East, Africa, and South America | Long term (≥ 4 years) |
报告关注的关键问题
What is driving demand for interchangeable biosimilars?
FDA pathway changes, pharmacy substitution, payer formulary actions, and biologic patent expiries support adoption. These forces matter most when a product can be supplied reliably and added to a payer's preferred treatment pathway.
How large is the interchangeable biosimilars market in 2026?
The interchangeable biosimilars market size is USD 3.62 billion in 2026 and is forecast to reach USD 4.96 billion by 2031. The forecast reflects a 6.50% CAGR during 2026-2031.
Which product type leads to interchangeable biosimilars?
Interchangeable monoclonal antibodies led product types with 47.45% of revenue in 2025. Adalimumab and ustekinumab support this position because they have mature prescribing pathways and several approved alternatives.
Which therapeutic area is growing fastest?
Oncology and hematology is forecast to grow at a CAGR of 7.98% through 2031. Future growth depends on candidates moving from development into approved interchangeable options for major cancer biologics.
Why are specialty pharmacies important for biosimilar uptake?
They manage prior authorization, patient outreach, clinical coordination, and cold-chain delivery during treatment transitions. These tasks can reduce disruption when a payer moves patients to a preferred alternative.
Which region is expected to grow fastest through 2031?
Asia-Pacific is forecast to expand at a CAGR of 8.76% through 2031. Regulatory changes in Japan and India can support development activity, although substitution practices remain different across the region.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence